welcome
Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Business

Business & Economics

Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
Summary
Nutrition label

81% Informative

Needham reiterated a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) on June 12 , keeping the price target at $ 10.00 .

Needham 's Gil Blum cited the promising results of the FELIX study for obe-cel in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) as one of the factors supporting the optimistic rating.

AutolUS Therapeutic company develops programmed T cell therapies for treating autoimmune diseases.

VR Score

78

Informative language

76

Neutral language

44

Article tone

formal

Language

English

Language complexity

67

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Source diversity

1

Affiliate links

no affiliate links